Closely monitor and control blood pressure. Pay particular attention to sudden stabbing migraine-like headache. Discontinue therapy if anti-erythropoietin, Ab-mediated PRCA is suspected; blood pressure cannot be controlled. Patients with epilepsy, history of seizures, or medical conditions associated with a predisposition to seizure activity eg, Central Nervous System infections and brain metastases; underlying haematologic diseases; porphyria; cancer. Increased incidence of thrombotic vascular events. Closely monitor hemoglobin concentration. Platelet count should be regularly monitored during first 8 week of therapy. Other causes of anaemia should be evaluated and treated prior to initiation of therapy and before decision to increase dose. Discontinue if a severe cutaneous reaction eg, Stevens-Johnson syndrome or toxic epidermal necrolysis is suspected. HIV-infected patients. Adult surgery patients in an autologous pre-donation programme and adult perisurgery patients without autologous blood donation. Not recommended in perisurgery patients with a baseline Hb of >13 g/dL. Chronic liver and renal failure. Pregnancy and lactation.
Sign Out
